Tango Therapeutics, Inc. (TNGX)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 8 | 37 | 25 | 37 | 42 | 62 | 54 | - |
| Operating profit | $m | -111 | -136 | ||||||
| Net profit | $m | -52 | -58 | -108 | -102 | -130 | -102 | -124 | -167 |
| EPS reported | $ | -0.87 | -0.85 | ||||||
| Operating cashflow per share | $ | -1.20 | -0.99 | ||||||
| Capex per share | $ | 0.01 | 0.01 | ||||||
| FCF per share | $ | -1.20 | -0.99 | ||||||
| Free cash flow | $m | -140 | -144 | ||||||
| Net debt | $m | -312 | -1,014 | ||||||
| Book value equity | $m | 346 | 1,025 | ||||||
| Book value per share | $ | 2.98 | 6.84 | ||||||
| Number of shares | m | 116.17 | 149.88 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 2.97 | 1.00 | ||||||
| P/S LTM | x | 16.50 | 19.13 | ||||||
| P/FCF LTM | x | -7.36 | -7.13 | ||||||
| EV/EBITDA LTM | x | -9.57 | -7.77 | ||||||
| EV/Sales LTM | x | 15.24 | 56.78 | ||||||
| Earnings Yield LTM | % | -9.87% | -2.77% | ||||||
| FCF Yield | % | -13.60% | -14.02% | ||||||
| Quality | |||||||||
| ROE | % | -29.35% | -41.54% | ||||||
| ROIC | % | -29.31% | -27.69% | ||||||
| Operating margin | % | -1.78% | -2.06% | ||||||
| Gross margin | % | +96.34% | +97.25% | ||||||
| FCF/Sales | % | -224.31% | -250.11% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +48.29% | +27.91% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -4.17 | -4.51 | ||||||
| Net Debt/EBITDA | x | 0.79 | 1.19 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | +3.00% | +0.89% | ||||||
| Net debt/Equity | x | -0.90 | -0.99 | ||||||
| Gross debt/equity | x | 0.10 | 0.03 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free